Wednesday, December 17, 2025 ALC9 (HEMATOLOGIC) - Expected: Q2 2026 myeloMATCH - (ERASE) Eradicating MRD in Patients with AML prior to Stem Cell Transplant ALC10 (HEMATOLOGIC) – Expected: Q1 2026myeloMATCH - Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML ALC11 (HEMATOLOGIC) - Expected: Q2 2026 myeloMATCH - ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML MD1 (HEMATOLOGIC) - Expected: Q2 2026myeloMATCH – (CALMS) Combination Therapy with Luspatercept in Lower Risk MDS CE10 (BRAIN) - Expected: Q1 2026 (VIGOR) Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma BR39 (LUNG) – Expected: Q4 2026(LUNA-2): LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial Q4 2026HN14 (HEAD & NECK) - Expected: Q3 2026 (REVERT) Delayed Reduced Volume and Dose Elective Ratiotherapy in Patients with HNSCC LYC2 (LYMPHOMA) – Expected: Q2 2026 Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT) ME18 (MELANOMA) - Expected: Q3 2026 (MSLT-3) The Multicentre Selective Lymphadenectomy Trial-3 - Selective Index Node Resection vs Lymph Node Dissection after Neoadjuvant Immunotherapy for Stage IIIB-D Melanoma PAC5 (GASTROINTESTINAL) - Expected: 2026 Lanreotide for the Prevention of Postoperative Pancreatic Fistula SC30 (SUPPORTIVE CARE) - Expected: Q4 2025 (RATIONAL-PT) Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial SC31 (SUPPORTIVE CARE) - Expected: Q1 2026 (TEMPO) Using SMART to optimize the stepped care delivery of a Tailored, dyadic, wEb-based physical activity and self-Management PrOgram for men with prostate cancer and their caregivers SC32S (SUPPORTIVE CARE) – Expected: Q1 2026Feasibility and Acceptability of Collecting Sociodemographic Data in CCTG TrialsSR8 (SARCOMA) - Expected: Q1 2027 (NAPStAR) NeoAdjuvant-only or Peri-operative cemiplimab in high-grade localised soft-tissue SARcoma MA42 (BREAST) - Expected: Q2 2026 (NoLEEta) No Chemotherapy in Intermediate-risk HR + HER2- Early Breast Cancer Treated with Ribociclib EN12 (GYNECOLOGY) – Expected: Q3 2026(RAINBO-ORANGE) Treatment of Endometrial Cancer Based on Molecular FeaturesIND246 (SELECTED SOLID TUMORS) – Expected: Q1 2026 (GCAR1) A chimeric antigen receptor (CAR) t-cell therapy in selected relapsed/refractory GPNMB-expressing alveolar soft-part sarcoma, renal cell carcinoma, and triple negative breast cancerIND245 (MANTLE CELL LYMPHOMA) – Expected: Q1 2026 Sonrotoclax and Zanubrutinib in patients with relapsed/refractory mantle cell lymphoma receiving standard of care CAR-t cell therapy MAC31 (BREAST) – with drawn
